Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract.
Philip Burnham,Darshana Dadhania,Darshana Dadhania,Michael Heyang,Fanny Chen,Lars F. Westblade,Manikkam Suthanthiran,Manikkam Suthanthiran,John R. Lee,John R. Lee,Iwijn De Vlaminck +10 more
TL;DR: It is found that urinary cfDNA is highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection.
Journal ArticleDOI
Multicenter Evaluation of the Accelerate PhenoTest™ BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis
Preeti Pancholi,Karen C. Carroll,Blake W. Buchan,Raymond C. Chan,Neelam Dhiman,Bradley Ford,Paul A. Granato,Amanda T. Harrington,Diana R. Hernandez,Romney M. Humphries,Matthew R. Jindra,Nathan A. Ledeboer,Shelley A. Miller,A. Brian Mochon,Margie Morgan,Robin Patel,Paul C. Schreckenberger,Paul D. Stamper,Patricia J. Simner,Nancy E. Tucci,Cynthia Zimmerman,Donna M. Wolk +21 more
TL;DR: The Accelerate Pheno system has the unique ability to identify and provide phenotypic MIC and categorical AST results in a few hours directly from positive blood culture bottles and support accurate antimicrobial adjustment.
Journal ArticleDOI
Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years.
Ana Fernández-Cruz,Patricia Muñoz,Rosa Mohedano,Maricela Valerio,Mercedes Marín,Luis Alcalá,Marta Rodríguez-Créixems,Emilia Cercenado,Emilio Bouza +8 more
TL;DR: Campylobacter bacteremia is no longer a significant disease of HIV-positive patients on HAART, but often affects other immunocompromised patients as well.
Journal ArticleDOI
Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies
TL;DR: The authors discuss carbapenem resistance in Acinetobacter baumannii, a bacterial isolate often implicated in nosocomial infections andTherapeutic options are exceedingly limited, relying on polymyxins in combinations with other antibiotics, with few, if any, new active agents in the pipeline.
Journal ArticleDOI
In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates
Barbara A. Brown-Elliott,Elena Iakhiaeva,David E. Griffith,Gail L. Woods,Jason E. Stout,Cameron R. Wolfe,Christine Turenne,Richard J. Wallace +7 more
TL;DR: This study presents in vitro amikacin MICs for 462 consecutive clinical isolates of the MAC using a broth microdilution assay and proposes MIC guidelines for breakpoints that are identical to the CLSI guidelines for Mycobacterium abscessus: ≤16 μg/ml for susceptible, 32 μg/ML for intermediate, and ≥64 μg/ ml for resistant.